omalizumab

Brand: Xolair

Prototype Drug
Drug Class: biologic — anti-IgE monoclonal antibody
Drug Family: biologic
Subclass: anti-IgE humanized monoclonal antibody
Organ Systems: respiratoryimmunology

Mechanism of Action

Binds free serum IgE preventing it from binding FcεRI receptors on mast cells and basophils; reduces high-affinity IgE receptor expression; decreases mast cell/basophil activation.

immunoglobulin E (IgE)

Indications

  • moderate-severe allergic asthma (IgE-mediated; baseline IgE 30-700 IU/mL)
  • chronic idiopathic urticaria
  • nasal polyps

Contraindications

  • not for acute bronchospasm
  • anaphylaxis history to omalizumab

Adverse Effects

Common

  • injection site reactions
  • upper respiratory infection
  • headache
  • nasopharyngitis

Serious

  • anaphylaxis (0.2% — delayed onset up to 24h after injection)
  • malignancy (signal in some studies)

Pharmacokinetics (ADME)

Absorption ~62% SC bioavailability
Distribution serum and tissues
Metabolism proteolytic degradation
Excretion hepatic proteolysis
Half-life 26 days
Onset 7-8 days
Peak 7-14 days
Duration 28 days
Protein Binding <0%
Vd 78 mL/kg

Drug Interactions

Drug / Agent Mechanism Severity
other biologics additive immunosuppression risk moderate

Nursing Considerations

  1. Administer by healthcare provider only (delayed anaphylaxis risk)
  2. Observe patient 2 hours after first 3 injections and 30 minutes subsequently
  3. Dose and frequency based on baseline IgE level and body weight
  4. Clinical response assessed after 16 weeks
  5. Does not prevent acute attacks — continue controller medications

Clinical Pearls

  • Anti-IgE: reduces mast cell and basophil sensitivity — fewer exacerbations, reduced OCS dependence
  • EXTRA trial: reduces asthma exacerbations by 25% in allergic asthma
  • Delayed anaphylaxis: up to 24 hours post-injection — educate patient and prescribe epinephrine auto-injector

Safety Profile

Pregnancy insufficient-data
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required